Publications by authors named "Frederick Wigley"

Claim this Profile
R
Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti-Interferon-Inducible Protein 16 Antibodies.
Zsuzsanna H McMahan, Frederick M Wigley, Livia Casciola-Rosen

Arthritis Care Res (Hoboken)· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients.
Chris Cheadle, Alan E Berger, Stephen C Mathai, Dmitry N Grigoryev, Tonya N Watkins, Frederick Wigley

PLoS One· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nodular/keloidal scleroderma: acquired collagenous nodules in systemic sclerosis.
Elizabeth N Le, Jacqueline M Junkins-Hopkins, Noelle S Sherber, Frederick M Wigley

J Rheumatol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haemopoietic stem-cell transplantation for systemic sclerosis.
Keith M Sullivan, Frederick M Wigley, Christopher P Denton, Jacob M van Laar, Daniel E Furst

Lancet· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.
Olga Gorlova, Jose-Ezequiel Martin, Blanca Rueda, Bobby P C Koeleman, Jun Ying, Frederick M Wigley

PLoS Genet· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival in systemic sclerosis-related pulmonary arterial hypertension in the modern treatment era.
Reda E Girgis, Stephen C Mathai, Frederick M Wigley, Paul M Hassoun

Am J Respir Crit Care Med· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
Arnold E Postlethwaite, Weng Kee Wong, Philip Clements, Soumya Chatterjee, Barri J Fessler, Frederick Wigley

Arthritis Rheum· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases.
T Rinda Soong, Lili A Barouch, Hunter C Champion, Frederick M Wigley, Marc K Halushka

Hum Pathol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products.
Kane L Schaphorst, Eddie Chiang, Keri N Jacobs, Ari Zaiman, Viswanathan Natarajan, Frederick Wigley

Am J Physiol Lung Cell Mol Physiol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bullous lesions in scleroderma.
Adrienne Rencic, Supriya Goyal, Mona Mofid, Frederick Wigley, H Carlos Nousari

Int J Dermatol· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis